Results 261 to 270 of about 18,481,212 (402)

Modulating IgG effector function by Fc glycan engineering

open access: yesProceedings of the National Academy of Sciences of the United States of America, 2017
Tiezheng Li   +5 more
semanticscholar   +1 more source

Systematic profiling of cancer‐fibroblast interactions reveals drug combinations in ovarian cancer

open access: yesMolecular Oncology, EarlyView.
Fibroblasts, cells in the tumor environment, support ovarian cancer cell growth and alter morphology and drug response. We used fibroblast and cancer cell co‐culture models to test 528 drugs and discovered new drugs for combination treatment. We showed that adding Vorinostat or Birinapant to standard chemotherapy may improve drug response, suggesting ...
Greta Gudoityte   +10 more
wiley   +1 more source

TSC22 domain family member 3 links natural killer cells to CD8+ T cell-mediated drug hypersensitivity. [PDF]

open access: yesSignal Transduct Target Ther
Sun L   +17 more
europepmc   +1 more source

Comprehensive omics‐based classification system in adult patients with B‐cell acute lymphoblastic leukemia

open access: yesMolecular Oncology, EarlyView.
The COMBAT classification system, developed through multi‐omics integration, stratifies adult patients with B‐cell acute lymphoblastic leukemia(B‐ALL) into three molecular subtypes with distinct surface antigen patterns, immune landscape, methylation patterns, biological pathways and prognosis.
Yang Song   +11 more
wiley   +1 more source

The accessory type III secretion system effectors collectively shape intestinal inflammatory infection outcomes. [PDF]

open access: yesGut Microbes
Biswas P   +9 more
europepmc   +1 more source

Ras and its effectors

open access: yesProgress in Biophysics and Molecular Biology, 1996
Christian Herrmann, Nicolas Nassar
openaire   +2 more sources

Circulating tumor DNA monitoring and blood tumor mutational burden in patients with metastatic solid tumors treated with atezolizumab

open access: yesMolecular Oncology, EarlyView.
In patients treated with atezolizumab as a part of the MyPathway (NCT02091141) trial, pre‐treatment ctDNA tumor fraction at high levels was associated with poor outcomes (radiographic response, progression‐free survival, and overall survival) but better sensitivity for blood tumor mutational burden (bTMB).
Charles Swanton   +17 more
wiley   +1 more source

Home - About - Disclaimer - Privacy